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Human  neuroimaging,  speciﬁcally  magnetic  resonance  imaging  (MRI),  is  being  used  with  increasing  pop-
ularity to study  brain  structure  and  function  in development  and  disease.  When  applying  these  methods
to  developmental  and clinical  populations,  careful  consideration  must  be taken  with  regard  to  study
design  and  implementation.  In this  article,  we discuss  two major  considerations  particularly  pertinent
to  brain  research  in special  populations.  First,  we discuss  considerations  for subject  selection  and  char-
acterization,  including  issues  related  to comorbid  conditions,  medication  status,  and  clinical  assessment.
Second,  we  discuss  methods  and  considerations  for  acquisition  of  adequate,  useable  MRI  data.  Given thatevelopment
europsychiatric disorders
nclusion/exclusion criteria
ock scanner
otion artifact
children and  patients  may  experience  anxiety  with  the  scanner  environment,  preventing  participation,
and  that  they  have  a  higher  risk of  motion  artifact,  resulting  in  data  loss,  successful  subject  compliance
and  data acquisition  are  not  trivial  tasks.  We  conclude  that, as  researchers,  we  must consider  a number  of
issues  when  using  neuroimaging  tools  to  study  children  and  patients,  and  we  should  thoughtfully  justify
our  choices  of methods  and  study  design.
ublisourette syndrome © 2015  The  Authors.  P
. Introduction
With the rising use of human neuroimaging techniques to
nswer research questions of developmental and clinical signiﬁ-
ance, there is increasing need for a comprehensive understanding
f strategies for collecting imaging data in special populations.
hile investigators continue to develop new approaches for
cquiring quality data, the ﬁeld would beneﬁt from further reﬁne-
ents and updated strategies to optimize the cost:beneﬁt ratio of
ur imaging studies. Here, we discuss two overarching consider-
tions for MRI  data acquisition in pediatric and clinical populations:
1) subject selection and characterization, and (2) methods for
cquiring adequate, high-quality imaging data. These topics often
rompt debate or criticism from reviewers for journals and fund-
ng agencies. Thus, it is important that these key issues be well
nderstood.
∗ Corresponding author at: Washington University School of Medicine, Depart-
ent of Psychiatry, East Building, Neuroimaging Laboratories, 4525 Scott
ve,  Suite 2220, St. Louis, MO  63110, United States. Tel.: +1 314 362 8898;
ax: +1 314 362 2186.
E-mail address: greened@npg.wustl.edu (D.J. Greene).
ttp://dx.doi.org/10.1016/j.dcn.2015.12.005
878-9293/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
In this article, we refer often to our own  experience collecting
data from children with Tourette syndrome (TS), which exempli-
ﬁes many of the key issues researchers face in acquiring data from
pediatric and clinical populations. TS is a neuropsychiatric disor-
der with childhood onset. Thus, many of the issues that arise in
TS research are similar to those in studies of typical development
as well as other childhood disorders, such as autism and attention
deﬁcit hyperactivity disorder (ADHD). TS is characterized by motor
and vocal tics, which are brief, unwanted movements or sounds
(Leckman et al., 2006; Black et al., 2014); common tics include
exaggerated eye blinking, head jerking, snifﬁng, and throat clear-
ing. Therefore, special considerations are required with respect
to motion during data acquisition, as is the case in studies of
child populations in general as well as other movement disorders,
including Parkinson disease and dystonia. Also, like many neu-
ropsychiatric disorders, TS has a high comorbidity burden, with
particularly high rates of comorbid ADHD and obsessive compul-
sive disorder (OCD) (Freeman et al., 2000). Moreover, patients
can be treated with behavior therapy (e.g., Piacentini et al., 2010)
or with a variety of psychoactive medications, including antipsy-
chotics, centrally acting adrenergic agents, and SSRIs (Black et al.,
2014; Eddy et al., 2011). Thus, issues that must be considered with
respect to comorbid conditions and medication status in studies
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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f TS also apply to research in other clinical populations. Further,
hile we focus here on MRI  data collection in typical and atypical
evelopment, the issues discussed apply to studies in a wide range
f clinical populations and across the lifespan.
. Considerations for subject selection and characterization
An important, early step for neuroimaging research is appro-
riate study sample selection. While sample selection may  seem
rivial initially (e.g., research aimed at studying TS will include chil-
ren with a diagnosis of TS), there are important issues to consider
hen determining study inclusion/exclusion criteria. One might
hink that the best approach to studying any neuropsychiatric pop-
lation is to restrict subject selection to a “clean” or “pure” sample
ith no comorbid conditions or current medications. While there
re scenarios in which this approach is appropriate, it is under-
ppreciated that such an approach can raise as many concerns as
t solves. Here, we discuss these concerns, offer our opinions, and
escribe strategies implemented in our own research studies.
.1. What is the ultimate goal of your research?
Investigators must consider the ultimate purpose of their
esearch program. When designing an experiment, researchers
egularly evaluate aspects of study design (including subject inclu-
ion/exclusion criteria) with respect to the particular experimental
uestion at hand. We  argue that in addition to considerations
elated to the speciﬁc experiment, investigators ought to reﬂect on
he overall motivation behind that study and the eventual goal in
he context of the greater research program. In other words, what
oes the “Signiﬁcance” or “Impact” section of the grant supporting
he work claim? Is the aim of the work to understand the neural
orrelates of a particular disorder as a whole rather than a single
ymptom? Is the overarching objective to inform future discovery
f better treatment targets or clinical care? In our own studies and
ften in other laboratories, the answer to these questions is “yes.” In
uch cases, results that are generalizable to most individuals with
he disorder are most desirable. Indeed, there is research aimed
t understanding and/or targeting one speciﬁc symptom (e.g., tics,
mpulsivity) of a complex disorder (e.g., TS, ADHD). For these stud-
es, it may  be more appropriate to take a restricted approach to
ubject inclusion in order to isolate the symptom under study. Yet,
esearchers must understand the important distinction between
tudying the mechanisms of a speciﬁc symptom and studying the
echanisms of a disorder. Typically, a disorder is characterized by
any types of symptoms—thus, the appellation “syndrome”. TS,
or example, while deﬁned by the involvement of motor/vocal tics,
ost often presents clinically with any one of a number of cogni-
ive and behavioral symptoms (Freeman et al., 2000; Martino et al.,
013). Therefore, any study of TS must consider whether the goal
s to investigate tics in isolation or the clinical presentation typical
f the majority of patients. If only a small percentage of individuals
ith the disorder have no other known neuropsychiatric problems,
s is the case with TS, research limited to understanding that small
raction of individuals may  have limited applicability, at least ini-
ially. Even a study focused on the neural mechanisms of tics (or
reating tics) in isolation with a clear justiﬁcation for studying a
ure and unmedicated sample is but a ﬁrst step toward under-
tanding TS as a whole. Such a study will require follow-up research
o test whether or not the ﬁndings generalize to those patients
ith more typical clinical presentation of the disorder (i.e., with
omorbid conditions, medication history). Moreover, if the trans-
ational signiﬁcance of the research is to inform future discovery
f treatments, researchers ought to consider whether the popu-
ation studied includes those individuals who are most likely toe Neuroscience 18 (2016) 101–112
seek clinical care (Gilbert and Buncher, 2005). Thus, when the ulti-
mate goal is to understand or treat the complex disorder, we argue
that ignoring those patients with the most typical clinical presen-
tations will limit the clinical applicability of the research, impeding
its ultimate purpose. In other words, we  prefer to collect an ecologi-
cally valid sample for most neuroimaging (and non-neuroimaging)
studies. There are two approaches one can take to achieve such
ecological validity: (1) ﬁrst study a pure sample, and then conduct
follow up research to test the generalizability of the results, or (2)
study a larger heterogeneous sample, and conduct subgroup analy-
ses to test the speciﬁcity of the results. Some may opt for the former
option, but we opt for the latter. Either way, an ecologically valid
sample will ultimately need to be studied in order to obtain truly
translational results.
We  recognize that ecological validity may  not be entirely fea-
sible for some neuroimaging research. For example, many MRI
studies in autism spectrum disorders (ASD) include only patients
with high-functioning ASD. Lower functioning ASD patients may
not be able to lie inside the scanner without sedation or may  not be
able to understand or comply with task instructions. Therefore, it is
not practical to include these lower functioning children with ASD
in an fMRI study of working memory, for example. In such cases, it is
defensible to exclude subjects who  could not practically participate,
but limitations in generalizability must be acknowledged. When
feasibility is not a limiting factor, however, we  recommend striv-
ing for ecological validity. In our own studies, we aim to place the
burden of heterogeneity on the analysis, not on narrowly focused
recruitment, allowing for data collection that best captures the
real-world population. Often, this strategy will necessitate large
sample sizes in order to capture the heterogeneity, i.e., including
both treated and untreated patients, and those with and with-
out diagnosed comorbid conditions. In the following subsections,
we discuss the less commonly considered issues with respect to
comorbid conditions and medication status that have informed
our decisions for subject selection, leading to our preference for
ecologically valid samples in most of our neuroimaging studies.
2.2. Considering comorbid conditions
Comorbidities are quite common, and for some disorders the
presence of comorbid conditions is the rule rather than the excep-
tion. TS is a prime example, as only 10% of individuals with TS have
no other known comorbidities (Freeman et al., 2000). The most
common comorbid conditions are ADHD and anxiety, most fre-
quently OCD. In fact, 50–60% of children with TS also have ADHD
and 30–40% also have OCD, and so TS, OCD, and ADHD are often dis-
cussed as an interconnected triad (Kurlan, 2010). Therefore, if one is
interested in studying TS as a condition, these common comorbidi-
ties must be considered. Selecting only those TS patients with no
comorbid conditions will be logistically difﬁcult from a recruitment
standpoint and will usually limit the generalizability of the results.
TS is not alone in this regard; mood disorders, anxiety, and sleep
disturbances often co-occur (Vazquez et al., 2014; Chorney et al.,
2008), ADHD is frequently comorbid with conduct disorder, oppo-
sitional deﬁant disorder, dyslexia, and learning disabilities (Pliszka,
1998; Germano et al., 2010), and substance abuse is highly comor-
bid with mood and anxiety disorders (Conway et al., 2006). Thus,
these principles apply to many studies of neuropsychiatric disor-
ders.
Reviewers of grants and research manuscripts often request
that inclusion and exclusion criteria result in “clean” or “pure”
samples of patient populations, meaning excluding all comorbid
conditions. It has become easy to make such a request reﬂexively,
and colleagues often support it as reasonable. We  argue that the
issue is more complicated, and requires careful consideration of
the consequences and limitations that arise when using pure vs.
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eterogeneous samples. One concern is that deﬁning a truly pure
ample is not straightforward. The recent release of DSM-5 high-
ights the fact that diagnostic criteria constitute a moving target. For
nstance, changes in the diagnostic criteria for TS from DSM-IV to
SM-IV-TR to DSM-5 included changes in diagnostic threshold and
ymptom duration, such that a child may  meet diagnostic criteria
nder one of these deﬁnitions but not the others. Even when the
riteria do not change, symptoms change over time within an indi-
idual, especially when considering developmental populations.
or example, a 7 year old child with “pure” TS at the time of study
ay  3 years later be a 10 year old child with TS, OCD, and a single
epressive episode, posing the question of whether this child was
ver really a case of pure TS. A similar concern applies retrospec-
ively, since both patient recall and clinical judgment are fallible
Kendler et al., 1993, 1999). Moreover, family history of neuropsy-
hiatric illness provides information about liability in the offspring,
et family neuropsychiatric history is almost never assessed in
euroimaging studies. Additionally, patients often have subclini-
al symptoms; a patient meeting diagnostic criteria for TS but not
or OCD or ADHD may  nevertheless have nontrivial compulsions
r hyperactivity. Altogether, it is problematic to claim deﬁnitively
hat a group of patients has one and only one neuropsychiatric
ondition.
The reﬂexive insistence on pure samples also ignores important
ealities that may  have unintended consequences for the validity
f a study. Depending on the disorder, a pure sample may  lead
esearchers to examine brain function in exceptional cases rather
han typical cases. In TS, in which the clinical presentation involves
igniﬁcant heterogeneity and high comorbidity, a pure sample will
onsist of the more rare cases. Thus, even if it were possible to
btain a truly clean sample, studying the 10% of TS patients with no
nown comorbid conditions (Freeman et al., 2000) and unmeasured
amily history likely will not yield results that are generalizable to
ost patients with TS. Similarly, a study of substance abuse that
xcludes the ∼40% of patients with comorbid mood disorders and
he ∼30% with comorbid anxiety disorders (Conway et al., 2006)
ill not best represent the clinical population. In these instances,
he most ecologically valid sample will include comorbidities, and
he implications of limiting the study population to the rare cases
ust be acknowledged. In addition, TS is exemplary of disorders
n which more severe symptoms tend to be associated with more
omorbidity. Consequently, an unintended byproduct of including
nly pure TS cases will be to limit the sample to those with milder
ymptoms. The patients that researchers and clinicians are most
nterested in helping are not the ones with the lowest symptomatic
urden. Thus, in disorders similar to TS, we recommend taking an
nclusive approach for most studies rather than limiting the sub-
ect pool to the least affected patients. As there may  be disorders
n which symptom severity is not related to comorbidity burden,
nvestigators must understand the factors affecting their popula-
ion of interest and carefully consider such factors when striving to
tudy an ecologically valid sample. Indeed, as we mentioned previ-
usly, some studies will be aimed at identifying the mechanisms of
 speciﬁc symptom (e.g., tics, addiction) in which more restrictive
nclusion criteria can be acceptable. However, when the greater
urpose of a body of work is to move toward clinical utility, the
esults ultimately will need to be tested for generalizability to a
real world” sample.
Pure samples are often advocated as a way  of controlling
or confounding variables. However, controlling for these seem-
ngly “confounding variables” by excluding comorbidities is not
s straightforward as it may  seem. For one, commonly comor-
id conditions are not necessarily confounding, most obviously
hen a large proportion of patients share that comorbidity. Con-
ounds suggest additive effects that can be removed or accounted
or with methods like regression and covariance. Rather, commone Neuroscience 18 (2016) 101–112 103
comorbidities may  be more aptly termed interacting variables, as
they interact in complex ways. Therefore, excluding for comorbid
conditions will ignore the complex interactions that are often inte-
gral to the disorder. Examples of these complex interactions include
ADHD in TS, or intellectual disability in autism. In addition, it has
been argued that the term “comorbidity” can reﬂect a limitation of
the diagnostic system, in which the “real disease” produces symp-
toms that span several current diagnostic categories. For instance,
Huntington disease is caused by an abnormality in a single gene,
but can cause chorea, dystonia, rigidity, depression, personality
changes, and dementia in different people or across time in the
same person. This idea underscores the importance of embrac-
ing the complexity that is the reality of neuropsychiatric illness.
Thus, just as studies with heterogeneous samples are expected to
acknowledge limitations, studies with pure samples must acknowl-
edge their limitations as well, particularly with respect to the
complexity of the disorder.
Though consideration of comorbidity will likely yield a com-
plex sample, not only will this complexity more validly represent
the true population, it will also be a fruitful avenue of study. High
comorbidity of certain disorders brings up the question of whether
the underlying brain mechanisms are overlapping or separable.
While there are certainly cases of TS without other diagnoses, the
large number of individuals with TS, OCD, and ADHD suggests
the possibility that the underlying neurobiological mechanisms
may  not ﬁt neatly within diagnostic lines. In fact, application of
latent class analysis has provided evidence to suggest some over-
lap, identifying multiple classes, including a TS + OCD class and a
highly heritable TS + OCD + ADHD class (Grados et al., 2008). Sim-
ilarly, an analysis of children with ADHD and autism identiﬁed
classes of ADHD alone and ADHD + autism, but not autism alone
(van der Meer et al., 2012). Thus, studies aimed at investigating
the overlapping and distinct neural correlates of these classes are
greatly needed. Even within a diagnosis, studies aimed at under-
standing the brain mechanisms underlying different collections of
symptoms would push the ﬁeld forward immensely. One inter-
esting ﬁnding to come out of an inclusive study design in adults
with TS found that three clinically-deﬁned subgroups showed
reduced cortical thickness in different brain regions (Worbe et al.,
2010). Patients with simple tics had cortical thinning in pri-
mary motor regions; patients with simple and complex tics had
cortical thinning extending from primary motor regions to pre-
motor, parietal, and prefrontal regions; and patients with tics
and obsessive–compulsive symptoms had cortical thinning in the
anterior cingulate cortex. Thus, including heterogeneous subjects
and conducting subgroup analyses allowed for the interrogation
of speciﬁc features relating to particular aspects of the disorder.
Furthermore, treating subjects with a mixture of symptoms as a
homogeneous group – whether mixing tics, obsessions, and com-
pulsions, or mixing different types of tics – can obscure ﬁndings and
may  be responsible for inconsistencies in the literature (Greene
et al., 2013). In fact, clustering methods and factor analysis of TS
symptoms have identiﬁed subgroups even within a so-called pure
TS group (McGuire et al., 2013; Cavanna et al., 2011). Additionally,
there is recent evidence that clinical symptoms are not the only
means by which to identify meaningful subgroups. Behavioral data
measuring multiple cognitive functions as well as fMRI data can be
used to identify behavior-based and imaging-based subgroups of
children with ADHD, and even subgroups of typically developing
children (Fair et al., 2012; Costa Dias et al., 2015). Thus, heteroge-
neous samples can be a virtue for many research questions, and can
be presented as such in grants and manuscripts.We  also argue that subjects in neuroimaging studies should
be characterized carefully clinically with reasonably deep pheno-
typing. For patients and controls alike, self-report of the presence
or absence of a diagnosis is frequently inaccurate (King, 1997).
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emi-structured clinical interviews greatly increase diagnostic reli-
bility and provide more accurate and comprehensive assessments
f clinical diagnoses. Clinical measures of current symptom sever-
ty (questionnaires or expert rating scales) can supplement –
r, depending on the research aims, even replace – diagnostic
nterviews. Collecting dimensional clinical and behavioral data in
ddition to MRI  data is crucial for improving the interpretability
f study results. Studies aimed at investigating a particular neu-
opsychiatric disorder should include dimensional assessments of
eatures that deﬁne the disorder as well as assessments of fea-
ures that commonly accompany the disorder. For example, our
tudies of TS include measures of tic severity (e.g., Yale Global Tic
everity Scale; Leckman et al., 1989), as well as OCD severity (e.g.,
hildren’s Yale-Brown Obsessive Compulsive Scale; Scahill et al.,
997), ADHD symptoms (e.g., Conners’ Rating Scale; Conners et al.,
998), and anxiety (e.g., Multidimensional Anxiety Scale for Chil-
ren; March et al., 1997), in addition to demographic information,
ehavioral measures of executive function, and general intelligence
Church et al., 2009a, 2009b; Stewart et al., 2015; Greene et al.,
015, in press). Assessments that capture a range of sub-clinical
nd clinical symptoms are ideal, as subjects in a comparison con-
rol group may  also exhibit symptoms below a clinical severity
hreshold. Similarly, behavioral measures of cognitive, motor, or
ensory functions can be administered to both patient and con-
rol groups, allowing for dimensional comparisons. Collecting such
ata will allow for careful characterization of all subjects, and
ill enable analyses investigating the relationships between brain
maging data and clinical and behavioral features. Additionally, for
he most complete and accurate assessments, collecting data from
ultiple informants is ideal. Given individual biases and the vari-
bility in how subjects or caretakers respond, relying on measures
ompleted by a single informant may  not be sufﬁcient. Thus, when-
ver possible, we encourage the use of multiple informants (e.g.,
arent/guardian and teacher for children, self and close friend or
elative for adults), either for questionnaires or clinical interviews
ith a trained professional. Some study questions may  even require
linical consensus diagnosis based on all available data (Bryant
t al., 1990). We  recognize that such an intensive evaluation of
ll subjects is not always feasible, and the extent of phenotyping
eeded will depend on a study’s speciﬁc aims. Admittedly, some of
ur previous studies lacked multi-informant assessment. However,
ur future studies will strive for a more complete approach and we
ncourage others to do the same.
.3. Considering medication status
Patients with neuropsychiatric disorders are commonly treated
ith psychoactive medications. There are several issues to con-
ider when including or excluding subjects due to past or present
edication use, similar to the issues discussed regarding comor-
idities. Often researchers assume that an unmedicated sample is
 preferable sample. This assumption can lead to reﬂexive demands
y reviewers for “medication-free” samples or by investigators
hemselves for unmedicated subjects. However, we argue that this
ssumption is not necessarily valid. While researchers readily point
o issues associated with medicated subjects, a number of concerns
lso arise when excluding medications, and these concerns are less
ommonly considered. We  do not mean to diminish the concerns
hat arise when including patients taking medications. Rather, we
im to enumerate the rarely discussed disadvantages of exclud-
ng medicated patients. These issues must be weighed against the
etter-known issues associated with including medicated patients,
nd adequately addressed in grant applications, grant reviews, and
anuscripts.
One major issue is that the deﬁnition of “medication-free” is
sed variably. The term can refer to patients who discontinue theire Neuroscience 18 (2016) 101–112
current medications during the study and for a washout period
before; it may  refer to patients with a past history of medication
use, but who are not currently taking medications; or it can refer
to patients who have never taken any psychoactive medications at
all. The common practice of treating all of these “medication-free”
subjects as equivalent is problematic. It is problematic to assume,
for example, that the brain of a chronically medicated subject who
does not take his/her medications the day of the scan is the same as
the brain of a subject who  has never taken a medication. Similarly,
one ought not assume that the brain of a subject who is currently
unmedicated, but has a history of medication use, is the same as the
brain of a subject with no medication history (Robertson, 1996). In
our experience, this issue is not regularly considered and subjects
who have never taken medications, those with medication history
who are currently unmedicated, and those who are currently med-
icated but discontinue medications for the experiment, are treated
the same and deemed an unmedicated, “clean” sample. However,
this unmedicated sample with hidden liabilities is not necessarily
cleaner than a medicated sample in which the liabilities are known
and taken into account.
Even when selecting a speciﬁc operational deﬁnition of
medication-free, one must understand the potential unintended
consequences. Excluding subjects with current medication use can
introduce practical and scientiﬁc issues. For one, depending on the
population under study, it can be difﬁcult to recruit a large enough
sample of unmedicated subjects to achieve sufﬁcient power for
neuroimaging research. Certain disorders necessitate medication
treatment for the majority of patients, and many of those who
are unmedicated may  not be ﬁt to participate in research (e.g.,
schizophrenia). In addition, certain recruitment sources do not
always easily reach unmedicated patients. For example, recruit-
ment via medical clinics will be limited by the patients seen at
the clinic, who  will often be medicated. Another issue to consider,
again, is ecological validity. When the goal of a research program is
to ultimately lead to novel targets for treatment and clinical care, a
study sample that includes those patients who would hope to bene-
ﬁt from such treatment and care (who will likely have a medication
history) is beneﬁcial. Excluding subjects who  are on medications
may  also produce unrecognized cohort effects. For example, such
exclusion may  bias the sample toward “healthier” patients, or in
the case of pediatric patients, may  select for patients whose parents
have an aversion to medical therapy. Of course, any such effects can
vary based on the study setting and population, but in the face of
such cohort effects, further study will be needed to ensure that the
results generalize to those patients who  actively seek treatment.
Another point of consideration is that investigators must be
aware of subjects’ treatment history. Patients who are not currently
medicated may  have a history of medication use, and that past
medication use likely affected the brain’s development. Further,
patients who have never taken medications during their lifetime
may have sought other forms of treatment, such as cognitive behav-
ioral therapy, which also likely affected the brain’s development.
Thus, their brains are not treatment-naïve. Even patients who have
not sought formal treatment, but have developed their own strate-
gies for coping or improving symptoms have likely experienced
brain changes. Therefore, a truly treatment-naïve sample with-
out any previous alterations in brain function would be difﬁcult to
obtain and would likely not be representative of the general patient
population.
Discontinuing current medications is another approach that
comes with its own  set of unintended consequences. One argu-
ment for this approach is to study a patient population in a
“natural” or “clean” state. However, the effects of temporarily dis-
continuing medications for the study visit may  interact with the
subject’s cognitive or affective state during the scan. Consider a
child with ADHD who has been taking a stimulant for years and has
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xperienced several beneﬁts. This child is typically on the stimu-
ant during school and in other settings when he/she is required to
o attention-demanding tasks. Thus, he/she is now accustomed to
oing such tasks while the stimulant is in effect. If the child is then
aken off the medication, placed in the MRI  scanner, and asked to
erform attention-demanding tasks, he/she may  be keenly aware
f the resulting performance decrement and become frustrated or
ngry. The child may  also approach the task with different cognitive
trategies than would a never-medicated child. Thus, researchers
hould recognize the potential adverse effects this experimental
aneuver can have on the subject’s brain activity, and weigh such
ffects against those of not discontinuing the medication. Depend-
ng on the speciﬁc study aims, one option may  be better than
he other. Requiring medication discontinuation can also introduce
election bias. In our experiences, those patients with more severe
ymptoms who depend on medications sometimes choose not to
articipate if there is a requirement to discontinue their current
edications even brieﬂy, also reducing the generalizability of the
esults. Additionally, withdrawal of some medications causes bio-
ogical changes that may  be more obvious than the effect of the
edication itself (e.g., alcohol withdrawal), or may  be more per-
anent (e.g., tardive dyskinesia). Moreover, there are likely still
rain effects of being chronically treated even if there has been
emporary withdrawal (e.g., all antidepressant medications exert
ffects over a period of weeks). Finally, many medicines (e.g. ﬂu-
xetine or primidone) have long effective half-lives, making brief
edication withdrawals futile. The point again is that withdrawing
 medication may  not be the same as not taking it in the ﬁrst place.
e recognize that there are circumstances in which medications
ave been shown to “normalize” brain measures (e.g., stimulants
n ADHD, Schweren et al., 2013) and by removing the medication,
ifferences between patients and controls can be more readily mea-
ured. Thus, the effects of discontinuing medications ought to be
onsidered regarding the speciﬁc characteristics of the class(es) of
edications and population under study.
Discontinuing medications for the purposes of research raises
everal ethical issues. For clinical trials investigating the efﬁcacy of a
edication, the risk of drug interactions can be an acceptable moti-
ation for discontinuing current medications, though even then
ne must consider problematic consequences (Gilbert and Buncher,
005). For other research, however, the ethical argument for
iscontinuing many psychotropic medications is weaker. Abrupt
iscontinuation sometimes will cause adverse side effects, from
SRI withdrawal syndrome (Schatzberg et al., 2006) to elevated
eizure risk from stopping sedatives. In addition, withdrawing an
ffective medication will likely worsen symptoms, and this wors-
ning may  last a considerable period of time for medications that
equire a long weaning period. Issues to consider when deciding
hether or not to discontinue medications include the subject’s
bility to give informed consent (e.g., the child’s parent/guardian
ust provide informed consent—the child can only provide assent),
hether discontinuation will cause problems beyond temporary
essation of the medication beneﬁts, the extent of beneﬁt the med-
cation is providing, and any side effects of the medication. These
ssues will vary depending on the study population and the class
f medication. For example, a study requiring discontinuation of
ntidepressants in adolescents with depression must consider the
otential dangers of worsening symptoms as well as potential dis-
ontinuation side effects that may  require a slow weaning period.
n the other hand, discontinuing stimulants for a study of chil-
ren with ADHD when the stimulant is the sole medication may
e less problematic, as stimulants have a faster washout period
nd withholding them for one or several days does not pose med-
cal concerns other than the worsening of ADHD symptoms. Thus,
hile there are circumstances in which taking children off their
edications for the purposes of research may  be acceptable, wee Neuroscience 18 (2016) 101–112 105
argue for the justiﬁcation to be thoughtful, clear, compelling, and
well communicated. Overall, potential ethical concerns need to be
considered and weighed for stopping each class of medication and
for each disorder under study.
We recognize that if an fMRI study shows differences in brain
activation between a patient group, all of whom are taking medica-
tions, and a control group, none of whom are taking medications,
the neuropsychiatric condition under study and medications are
confounded (though this extreme case is highly unlikely). Most
investigators do not want to publish a ﬁnding that may  be entirely
attributable to medication-induced brain changes. At the same
time, we have been arguing that an ecologically valid sample is
beneﬁcial in order to generalize research results to those patients
with signiﬁcant burden. Thus, we generally prefer to relax medi-
cation exclusions in our studies, with the goal of obtaining a large
sample that includes patients both on and off medications. Given
that neuroimaging study samples sizes are steadily increasing, the
analysis of subgroups is more feasible. In a study of 40 individuals
with depression, half of whom are taking antidepressants, analysis
of subgroups can test for effects that are speciﬁc to medications.
Of course, the power of subgroup analyses will depend on a num-
ber of factors, including subgroup sizes, the speciﬁc experimental
questions being asked, and the number of different medication
classes included. This approach must also address potential sever-
ity differences between subjects with and without medications.
In addition to subgroup analyses, there are statistical strategies
that (combined with appropriate sample selection) can account for
medication effects, such as including medications as factors in an
analysis of variance. Thus, we  contend that by placing the burden
on the analyses, recruiting samples of adequate size improves gen-
eralizability and clinical signiﬁcance compared to excluding large
groups of patients. If the goal of a research program is to under-
stand a disordered population, our position is that inclusion criteria
should be structured to capture as many exemplars of the disorder
as possible, in order to understand how interacting variables are
relevant to the phenotype and endophenotypes of the disorder.
2.4. Considerations for control groups and studies of typically
developing children
Control populations are often not well characterized, especially
in neuroimaging studies. Thus, there are many factors that may
inﬂuence the results of studies that include typically develop-
ing children. The ﬁeld has taken a step in the right direction, as
many studies now estimate IQ. Yet, more extensive characteri-
zation is needed. Of course, it is not clear what information will
be the most useful, and there exist a large number of measures
that can be assessed. Thus, choices can be informed by the par-
ticular research questions and by the populations under study. In
a study of typical development, such as those measuring growth
curves of brain structure (e.g., Giedd et al., 1999; Sowell et al., 2004;
Thompson et al., 2000), measures of pubertal status are often useful
(e.g., Carskadon and Acebo, 1993), as hormones can inﬂuence brain
development and age is not always an adequate proxy for pubertal
stage. In studies in which a patient population is being compared
to a control group, it is useful to assess clinical characteristics in
the control group in addition to the patient group. Just because
a control subject has never received a formal diagnosis does not
mean that he/she does not have any neuropsychiatric problems.
For example, many children may  not meet diagnostic criteria for
ADHD, but still have sub-clinical attention problems that inﬂuence
daily life and hence, brain function. In fact, one large, careful epi-
demiological study of youth in rural America found that 21% of
children in the population met  criteria for one or more DSM-IV psy-
chiatric disorders in the past three months, yet only 36% of those
diagnosable children had received any mental health care in the
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ame three-month period (Angold et al., 2002). Additionally, chil-
ren without clinical diagnoses at the time of study may  go on to
evelop diagnoses later in childhood or adolescence. Conversely,
 child may  have had past symptoms that went unnoticed or that
arents do not recall. For example, a direct observational study of
ics found at least one motor tic in 47% of ﬁrst-graders, but in only
5% of 6th-graders (Snider et al., 2002). Most of the “missing” 32%
n 6th grade would likely deny a history of tics, since no studies
ave found a prevalence of chronic tics greater than ∼10%. In these
ases, was the child a valid control subject at the time of study?
f course, controlling for future development of neuropsychiatric
llness or for past, unnoticed symptoms is quite difﬁcult with-
ut life-long longitudinal study, which is not realistically feasible.
ultiple-informant semi-standardized diagnostic interviews such
s the Kiddie-Schedule for Affective Disorders and Schizophrenia
K-SADS) (Kaufman et al., 1997) can provide a reasonable surro-
ate, though at a substantial cost. In some cases, family history
ay  be an appropriate proxy for past or future risk of disorder in
hildren.
When designing a research study and deﬁning inclu-
ion/exclusion criteria for a control group, it is worth considering
hether or not the control group should be excluded for medi-
ations and/or conditions commonly comorbid with the disorder
nder study. For example, a study of TS with liberal inclusion
riteria for the patient group may  consider whether or not it would
e appropriate to apply the same criteria to the control group. Such
ecisions may  depend on the scope of the study. A smaller-scale
tudy with limited funds or a pilot study may  beneﬁt from exclud-
ng comorbidities and medications in the control group (regardless
f the criteria for the patient group) in order to best differentiate
atients and controls. On the other hand, this choice may  confound
nterpretation of group differences. A large-scale or multisite study
apable of recruiting large numbers of subjects may  beneﬁt from
eing inclusive and analyzing subgroups within the controls as
ell as within the patients. For instance, a well-matched control
roup for a TS study in which 40% of tic subjects have ADHD may
ell be a tic-free control group ∼40% of whom also have ADHD.
his choice will largely depend on feasibility and the questions
t hand. In any case, justiﬁcation should be made for choices
egarding inclusion/exclusion of control samples in addition to
atient samples.
Just as one cannot assume that any particular patient group is
omogeneous, nor can one assume that a control group is homoge-
ous. In fact, there is evidence for behavior-based subgroups
f typically developing children. Fair et al. (2012) demonstrated
istinct subgroups of typically developing children based on
europsychological performance, including measures of working
emory, response inhibition, response variability, response speed,
nterference control, temporal information processing, and arousal
nd activation. Further, they found support for the idea that the
eterogeneity in children with ADHD is nested within the normal
ariation shown in typically developing children. These results sup-
ort the importance of collecting neuropsychological assessments
rom patients and controls alike. Interestingly, subgroups within
ypically developing children and children with ADHD can also be
eﬁned by fMRI data (Costa Dias et al., 2015). Thus, rather than com-
aring an entire group of children with ADHD to a group of controls,
omparisons within subgroups may  prove to be more informative.
.5. Studying subjects who can hold still in the scanner
Neuroimaging researchers must also be aware of potential
ohort effects speciﬁc to MRI  studies. Some groups of subjects
nevitably move more than others (e.g., children tend to move more
han adults) and some neuropsychiatric conditions are even char-
cterized by abnormal movement: TS involves tics, ADHD involvese Neuroscience 18 (2016) 101–112
hyperactivity, Parkinson disease involves tremor, etc. Given the
susceptibility of MRI  data to motion artifact, which we discuss
below, studies of these populations will necessarily be limited to
those individuals who can hold still in the scanner. This issue brings
up the question of whether or not we are capturing data that are
truly representative of the population under study. In patient popu-
lations, conceivably only the least affected patients will be able to
hold still during the scan. Interestingly though, in our experience
with TS, some patients with clinically severe tics can hold quite
still in the scanner, whereas some patients with clinically mild tics
cannot hold still at all. Nevertheless, there may  be a discrepancy
between the amount of movement a subject exhibits on an aver-
age day and the amount of head movement present in the scans
retained for analysis, in which case we may  not be capturing data
from the brain at the moments in time that are most typical for that
subject. The sensitivity of MRI  data to motion artifact renders these
problems unavoidable. Since we know group differences in motion
can introduce spurious results in MRI  data (discussed below), our
view is that matching head motion across groups is preferable to
including subjects whose data are contaminated by motion. Other
selection biases inherent in MRI  studies include studying subjects
who are not wearing orthodontic braces or who  do not have claus-
trophobia. Of course, we  must recognize and acknowledge these
resulting cohort effects.
Furthermore, it is worth noting that there are a number of
additional cohort effects that, while not speciﬁc to neuroimaging
studies, nevertheless face neuroimaging researchers. For exam-
ple, we can only scan subjects who  are compliant, a concept that
applies widely to human subjects research. Other unintentional
selection biases could include living near a research center and hav-
ing a parent with a ﬂexible work schedule. When studying patient
populations, there may  be clinical features that differentiate groups
other than the deﬁning features of the disorder (e.g., lower IQ, sen-
sory deﬁcits). These cohort effects are also sometimes unavoidable,
and partly why  we  advocate for inclusive, larger studies, in order
to tease out those factors in post-hoc analyses.
3. Strategies for obtaining adequate data
Once a study sample has been selected, neuroimaging
researches must strive to obtain useable imaging data. Collecting
MRI  data from pediatric and clinical populations comes with sev-
eral challenges and has necessitated continual improvements in
methods. The most common challenges are subject anxiety in
the scanner environment, and head movement in the scanner
(Poldrack et al., 2002; Bookheimer, 2000; Kotsoni et al., 2006).
Failure to address these issues proactively can lead to loss of data
due to aborted scans or excessive motion artifact. Additionally, the
researcher loses valuable time, research funds, and other resources.
Perhaps more importantly, inadequate attention to these issues can
also produce misleading results (Power et al., 2012; Reuter et al.,
2015; Yendiki et al., 2013; Le Bihan et al., 2006; Van Dijk et al., 2012;
Satterthwaite et al., 2012). These problems also have ethical conse-
quences, because if the research value to society is lower, so is the
beneﬁt:risk ratio for human subjects. Fortunately, several strate-
gies can ameliorate these difﬁculties, though advancements in our
methods are still needed. Herein we  discuss the use and efﬁcacy of
current strategies.
3.1. Scanner environmentThe MRI  scanner environment will be unfamiliar to many
research subjects, and this unfamiliarity will translate to vary-
ing levels of excitement and anxiety in each subject. Given the
fundamental goal of acquiring adequate imaging data, the ﬁrst
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tep must be to ease this anxiety and make the experience as
omfortable, pleasant, and child-friendly as possible. In addi-
ion, changes in subjects’ cognitive and affective states can affect
rain activity and other physiological measures that inﬂuence
maging results, including respiratory rate, heart rate and mus-
le tension (e.g., Drevets et al., 1992). Moreover, if the subject
s asked to return for longitudinal follow-up or is invited to
articipate in another study, a comfortable, pleasant experience
ill increase chances of continued participation. Successful devel-
pmental neuroimaging laboratories have taken several steps
o minimize anxiety in the scanner. No one prescription will
ork for all children or special populations, and the experi-
enter must be ﬂexible in response to the needs of each research
articipant.
Investigators generally agree that familiarizing children with
he scanner environment before the scan itself is important.
ne strategy for familiarization is to show the child (and par-
nt/guardian) a video that describes the MRI  procedure in a
hild-friendly manner. Videos have been created by different
roups, including Stanford University (http://cibsr.stanford.
du/participating/GettingReady/HomePreparation.html) and
he University of Texas, Austin (https://www.youtube.com/
atch?v=O6hQeqp5-EI&feature=em-share video user). Creating
 video speciﬁc to your institution’s MRI  setup may  be beneﬁcial,
hough time consuming. Investigators can also offer at-home
amiliarization with the scanner sounds using audio recordings of
everal different scan sequences. Extensive protocols that use these
nd additional approaches have been developed to make scanning
hild-friendly. One example is the “submarine protocol” targeted
oward 5- and 6-year-old children (Theys et al., 2014). Children
mbark on a “submarine adventure” consisting of extensive
re-scanning activities, including watching a video of “Whally the
hale,” popping bubbles with the researcher, crawling through a
mall tunnel while wearing ear plugs and headphones, and other
ngaging activities. For the MRI  scan session, the scanner room is
ecorated as an underwater environment and the scanner itself
s decorated as a submarine in order to continue the submarine
heme. This protocol resulted in 95% of 5- and 6-year-old children
ompleting the full scan session, suggesting success in easing
nxiety.
A widely used method for familiarization with the scanner envi-
onment is the use of a mock scanner, which is a replica of the
RI  scanner without the magnet. Commercial mock scanners often
onsist of a bore with a mechanically or manually operated bed
nd mock head coil. They may  also include a mirror and back pro-
ection system or visual presentation goggles, simulating the real
canner environment. Audio recordings of scanner sounds can be
layed through speakers in the bore. Subjects can spend time in the
ock scanner, becoming comfortable lying in the bore and listening
o the scanner sounds. For particularly anxious children, we have
aken the approach of putting the parent/guardian inside the mock
canner ﬁrst, allowing the child to press the button that controls
he scanner bed. The child can then take turns with his/her parent
oing inside the bore. Detailed mock scanner protocols have been
ublished (de Bie et al., 2010; Raschle et al., 2009; Barnea-Goraly
t al., 2014). Since commercial mock scanners involve signiﬁcant
ost, it may  not be feasible for some institutions to acquire such a
et-up. Fortunately, an inexpensive alternative practice set-up that
ses a toy tunnel has been shown to work as well as a commer-
ial mock scanner for obtaining T1- and diffusion-weighted scans
Barnea-Goraly et al., 2014).
During the MRI  scan, there are strategies that can be imple-
ented to create a child-friendly experience. For younger children,
 fairly simple approach is to allow the child to bring a stuffed ani-
al  (MR  compatible) into the scanner. Experimenters can also use
 parent’s presence to alleviate anxiety. However, the effects of ae Neuroscience 18 (2016) 101–112 107
parent’s presence can vary from child to child. Some children may
be most comfortable with their parent in the scanner room, some
may  need to talk to their parent over the intercom, and some may  be
more comfortable without their parent in the MRI  suite at all. Again,
being attentive to the child’s needs and being ﬂexible in response to
those needs is critical. Moreover, the experimenter must prospec-
tively and consistently address safety issues involved in allowing
parents into the scanner room. Another way to make the experience
pleasant is to show the child a movie whenever possible. For every
scan, we make sure that a movie or television show of the child’s
choice is cued and ready, and we  begin playing the movie as soon as
the child is inside the bore. Even if the child will only be watching
the movie for a few minutes at a time, this strategy ensures that
he/she will have something fun to watch while the experimenters
ﬁnish setting up and run the initial scans (e.g., localizer). An addi-
tional tip that we  have implemented for the especially anxious child
is to explain that the ﬁrst scan (the localizer) is very short (∼10 s),
so they can see what a real scan is like in the amount of time it takes
to count to ten in their head. In our experience, anxious children
have responded well to this information. Some investigators opt to
use shorter scan runs based on the assumption that shorter runs
will be more tolerable for children. In calibrating the duration of
resting-state fMRI runs from our experiences, we  have found that
7-min runs are just as tractable as 5-min runs for most children
that we have scanned. For those children who could not tolerate
the scan and chose to stop, attempts at shorter runs did not seem
to make a difference with respect to our ability to gather usable
data.
3.2. The problem of head movement
Head movement in the scanner during structural and functional
MRI  data acquisition is known to disrupt the signal and cause arti-
facts. The assumption from the data analysis standpoint is that each
voxel represents signal from one part of the brain. Unfortunately,
even if the subject shifts his/her head by only half the width of a
voxel (e.g., 2 mm),  the data collected from each voxel will include
signal from two different parts of the brain. At a minimum, motion
will result in blurring of the image, which can reduce apparent vol-
ume, density or activity (Reuter et al., 2015; Smith and Nayak, 2010;
Friston et al., 1996).
For fMRI data, motion will affect each voxel’s measured blood
oxygenation level dependent (BOLD) timecourse, reﬂecting sig-
nal from multiple voxels and altering signal intensity. There has
been recent increasing interest in, and use of, functional connec-
tivity MRI, which measures temporal correlations of BOLD signal
between brain regions. Recently, it was  discovered that this method
comes with a very problematic, unforeseen motion artifact: small,
sub-millimeter head movements systematically affect fMRI corre-
lations (Power et al., 2012; Van Dijk et al., 2012; Satterthwaite et al.,
2012). Speciﬁcally, correlations between spatially proximate vox-
els are inﬂated compared to correlations between spatially distant
voxels. In other words, even very small, repeated head movements
can introduce false correlations. For between-group analyses, this
effect of motion can lead to spurious results when one group
systematically moves more than the other. Thus, this issue is par-
ticularly critical to consider in studies that compare different age
groups or patient populations, and has called into question pre-
vious functional connectivity ﬁndings in development and aging
(e.g., Andrews-Hanna et al., 2007; Fair et al., 2007). There have also
been recent discoveries that small head movements can lead to sys-
tematic artifacts in structural MRI  measures, including volume and
thickness measures (Reuter et al., 2015) and diffusion weighted
imaging measures (Yendiki et al., 2013; Koldewyn et al., 2014).
Thus, reducing head movement during data acquisition is critical
for data quality and retention.
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.3. Methods to reduce head movement
There are a number of strategies that are commonly used in
rder to reduce the amount of head movement in the MRI  scanner.
rior to the MRI  scan, children can practice holding still while lying
own. A group at Stanford University developed a “statue game”
http://cibsr.stanford.edu/participating/Games.html) that children
an play at home, earning stickers for holding still (visually deter-
ined by a parent/guardian) for increasing lengths of time. Thus,
hildren can practice holding still before even setting foot in the
esearch environment. Experimenters have developed interesting
nd creative ways to continue this preparation during the study
isit itself. For example, as part of the submarine protocol men-
ioned above, children practice holding still while balancing a piece
f candy on their nose (Theys et al., 2014). Some groups also show
hildren pictures of crisp and blurry images (brains, cats, etc.) to
onvey the consequences of movement and the importance of hold-
ng still (Theys et al., 2014; Raschle et al., 2009).
Most commonly, investigators use a mock scanner for move-
ent training. Some mock scanners are equipped with real-time
otion tracking, in which a sensor detects the child’s head position.
sing this technology, the child can receive online visual feedback
f his/her head movement. Some software packages (e.g., MoTrak
ead Motion Tracking System, Psychology Software Tools, Inc.)
llow the subject to view a bulls-eye on a screen and a moving
rosshair that represents his/her head position. Subjects can then
ractice keeping the crosshair in the center of the bulls-eye by
olding still. Subjects can also be shown a movie that will pause
f head movement exceeds a set threshold. Thus, children are able
o acquire a sense for the sensitivity of the scanner to movement
nd can undergo some level of operant conditioning. One caveat
hould be mentioned regarding motion sensors that are placed on
he forehead. We  have found that in children with TS, most of whom
ave facial tics, the motion sensor is inaccurate when the child is
iccing. For example, the motion sensor will move when the child
aises his/her eyebrows or scrunches his/her nose even if the child’s
ranium remains quite still. In these circumstances, motion training
an be frustrating and likely ineffective. On the other hand, snifﬁng
r small movements of the lips or tongue often cause detectable
hanges in the position of the brain.
While the usefulness of mock scanner training for minimizing
otion is generally accepted, the empirical evidence for its effec-
iveness is limited. For example, fairly liberal thresholds, which may
ot effectively reduce motion-related effects, have been used to
ssess scan quality after training (de Bie et al., 2010; Epstein et al.,
007). Given the recent evidence that sub-millimeter movements
re problematic for functional connectivity data, stricter criteria
ay  be needed. Most striking is that we were unable to ﬁnd any
tudies in the literature that included a proper experimental con-
rol group. Since testing the effectiveness of mock scanner training
as not the primary aim of most studies reporting on mock scan-
ing, all subjects received the training. Consequently, it is difﬁcult
o assess whether the success rates reported, e.g., 70–100% useable
cans (de Bie et al., 2010; Barnea-Goraly et al., 2014) or decreased
otion during actual vs. mock scan (Epstein et al., 2007), were
ttributable to mock scanner training. Thus, it remains an empirical
uestion whether or not mock scanner movement training signif-
cantly improves movement during MRI  scans, and if it does, what
ethod or amount of training is sufﬁcient.
During the actual scan, several measures can be taken to increase
he chances of acquiring useable data. Physical restraints are some-
imes used, including bite bars, masks, cushions around the head,
acuum packs, and tape across the forehead. Some of these options
re more easily tolerated than others. For example, thermoplastic
asks, which mold to the shape of the subject’s face, are more com-
ortable than a bite bar, which requires clenching one’s teeth on ane Neuroscience 18 (2016) 101–112
object placed in the mouth. When these options are not available,
cushions or vacuum packs can be placed around the subject’s head
to maintain head position. Placing tape across the subject’s fore-
head is an easy option, which does not restrain head movement
per se, but serves as instant sensory feedback if movement occurs.
Again, however, we are unaware of controlled studies testing the
efﬁcacy of these methods. Furthermore, certain clinical populations
(e.g., TS, autism) are exceptionally uncomfortable having some-
thing touching the face.
3.4. Methods to account for head movement
Despite best efforts to minimize head movement during data
collection, the strategies just discussed do not completely eradicate
motion in the data. Particularly when collecting data from develop-
mental and clinical populations, it is nearly inevitable to have some
degree of motion contamination. Thus, researchers have developed
approaches to assess data quality and to account for motion in
acquired data during processing and analysis.
For T1-weighted structural MRI  scans, motion results in visi-
ble banding artifacts in the images and reduced gray matter/white
matter contrast. Thus, researchers often adopt qualitative (visual
grading of images) and/or quantitative criteria (errors in automated
segmentation software, such as Freesurfer) by which to exclude
subjects with too much artifact. For fMRI data, motion can be com-
puted from realignment estimates, allowing investigators to obtain
quantitative measures of movement in functional scans. Summary
estimates have traditionally been used to assess which subjects and
fMRI scan runs can be included in the data analysis. For exam-
ple, an investigator might set a threshold for average motion at
1.5 mm,  and any run with average motion exceeding 1.5 mm root
mean square (rms) will be excluded from data analysis (as in Church
et al., 2008). However, investigators must be aware of the different
ways by which motion estimates can be calculated. Motion can be
computed as absolute displacement from a reference frame (time-
point) or as relative displacement on a frame-by-frame basis, and
different calculations can be applied to obtain the estimates (e.g.,
root-mean-square, summing absolute values). Thus, understanding
the speciﬁc approach used in any given study is important, as the
scales can differ across studies depending on the reference frame
or calculations employed (Power et al., 2015).
Nearly every processing stream for fMRI data includes steps
aimed at correcting head movement, including spatial realignment
and regressing motion estimates. Given the discovery that sub-
millimeter movements systematically affect correlations in fMRI
signal timeseries, additional processing methods are needed to bet-
ter account for motion artifact in functional connectivity data. Thus,
there has been continued development of data processing methods
to reduce these effects. For example, some investigators propose
methods that include nuisance regressors, beyond those commonly
used in functional connectivity preprocessing, that better account
for local signal (Jo et al., 2013; Muschelli et al., 2014). Others have
used group-level covariates of no interest, which are effective in
reducing motion-related group differences, but also remove effects
of interest that are collinear with the covariate (Satterthwaite et al.,
2012). Our laboratory has devised and implemented a data pre-
processing approach that involves volume censoring and global
signal regression to minimize motion artifact (Power et al., 2014).
Volume censoring involves excising from data analysis BOLD vol-
umes with frame-by-frame movement (framewise displacement:
FD) exceeding a strict threshold (e.g., 0.2 mm),  thereby excluding
movement-contaminated data points. While a consensus has not
been reached as to which method works best, or even on how to
measure success of these methods (for detailed assessment and
review of multiple methods, see Power et al., 2015; Yan et al., 2013),
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Fig. 1. Pictorial display of resting state fMRI gray matter signals from 2 adult subjects. Top 2 panels show movement traces (top) and gray matter signal intensity (second
from  the top). The middle 3 gray panels show the effect of regressing increasing numbers of motions parameters. The bottom panel shows the effect of regressing the global
signal.  Yellow arrows point to examples of motion artifact that remain in the data until global signal regression is applied. FDPower: framewise displacement as calculated in
Power et al. (2012); WM:  white matter signal; CSF: ventricle signal; GS: global signal (whole-brain average); R: realignment estimates (6 parameters representing translation
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here is no question at this point that ignoring head movement can
roduce artifactual groupwise functional connectivity results.
Whichever method one chooses to implement, we  recommend
areful examination of the data for residual artifacts. For exam-
le, visual inspection of individual subjects’ BOLD signal across
ime in gray matter voxels reveals visible artifact that is removed
fter global signal regression (Fig. 1)1. In addition, thresholds for
ovement criteria largely depend upon the data itself. While our
aboratory uses an FD threshold of 0.2 mm for our 3T resting
tate fMRI dataset acquired using particular scan sequences, other
atasets may  require different thresholds. “A practical corollary
s that if FD measures are to be used in some dataset, FD wave-
orms and magnitudes should be established (and reported) for that
peciﬁc dataset, since magnitudes from the literature may  not be
ppropriately scaled to the data at hand” (Power et al., 2015). Thus,
t is recommended that researchers examine their data carefully
nd publish such examinations.
Compared to functional connectivity data, task fMRI data is less
ystematically affected by very low amplitude head movements.
f course, investigators ought to test whether motion correlates
ith task conditions (i.e., subjects move more during condition A
1 Reprinted from Neuroimage, vol. 105, Power JD, Schlaggar BL, Petersen SE,
ecent progress and outstanding issues in motion correction in resting state fMRI,
g.  536–551 (2015), with permission from Elsevier.36 are [R R2 Rt−1 R2 t−1 Rt−2 R2 t−2], where subscripts represent the estimates from
d the superscript 2 means squared. Figure modiﬁed from Power et al. (2015).  (For
 web  version of this article.)
than during condition B) in order to ensure that task effects are not
driven by movement. Generally, sub-millimeter movements do not
systematically affect groupwise results for task fMRI studies, mak-
ing it less imperative to include additional processing steps like
those used in functional connectivity studies. Interestingly though,
task fMRI data quality can be substantially improved by more assid-
uous attention to these sub-millimeter amplitude head movements
(Siegel et al., 2014).
In order to increase the odds of retaining useable data, we
recommend collecting more data. Averaging multiple T1 weighted
images, for example, often results in better estimates of structural
measures. For task fMRI, the precise amount of data largely depends
on the parameters of the task, but collecting additional runs may
preserve a subject who would otherwise be excluded. For resting
state fMRI, more data will reduce the likelihood of losing the subject
entirely in the analysis, particularly when implementing process-
ing methods that require removal of movement-contaminated
data. There has been a prevailing idea that 5 min of resting state
fMRI data was sufﬁcient to measure resting state networks (Van
Dijk et al., 2010), leading many groups to implement a practice of
adding one 5-min resting state scan to the end of other scanning
protocols. However, advances in the ﬁeld and updated information
now argue against this practice. For one, some of the most careful
data processing methods to account for motion artifact require
excising volumes of BOLD data (volume censoring, as discussed
above). Therefore, if only 5 min  are collected, it is likely that less
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han 5 min  will survive stringent processing thresholds, particu-
arly when scanning children and patient groups that tend to move
ore. In addition, there is evidence that 5 min  of resting state
ata has only moderate reliability for an individual’s functional
onnectivity proﬁle (Van Dijk et al., 2010; Shehzad et al., 2009).
or investigators interested in individual subject functional con-
ectivity, 10–25 min  of usable resting state data is recommended
f one wants to obtain reproducible measurements (Anderson
t al., 2011; Laumann et al., 2015), while more than 30 min  may  be
equired for more complex analyses with ﬁner spatial speciﬁcity
Laumann et al., 2015). It is understandable that shorter scan runs
nd scan sessions are attractive when studying children and other
pecial populations, and longer scan times may  reduce a subject’s
bility to tolerate the scan. However, given its susceptibility to
otion, fMRI data loss is inevitable, and losing subjects altogether
s quite undesirable. It is more expensive to recruit and bring in
dditional subjects than to spend more time with each one. Thus,
e encourage collecting more data while implementing strategies
hat can help with tolerability, such as taking brief breaks during
cans and repeat scan days. Of course, future advances in image
cquisition or data analysis may  allow shorter acquisitions for
ertain analytic purposes (e.g., Miranda-Dominguez et al., 2014).
There has been increasing effort to develop MRI  sequences that
elp reduce the adverse effects of motion. For structural MRI  scans,
 prospective motion correction technique was developed that
mplements spiral navigator scans and online motion tracking so
hat images tainted by movement can be reacquired (Brown et al.,
010; White et al., 2010). Use of this method results in better
uality scans assessed by both qualitative (visual inspection of the
mages) and quantitative measures (fewer errors in Freesurfer cor-
ical surface reconstruction and improved reliability of subcortical
olume measurements). For functional MRI  scans, the emergence
nd continued development of multi-echo sequences has sparked
nterest in the potential beneﬁts these sequences may  have for
ata quality (Kundu et al., 2012). By acquiring BOLD data at more
han one timepoint during a single TR, the idea is that real signal
an be more readily distinguished from artifactual signal. Multi-
cho sequences may  also allow computation of quantitative R2*
mages that may  be more stable over time, addressing a key limita-
ion of traditional BOLD imaging (Chen et al., 1996). However, it is
resently unclear whether or not multi-echo sequences will signif-
cantly reduce motion artifacts (Power et al., 2015). Thus, methods
evelopment for improving MRI  data acquisition (and analysis) is
 continuing ﬁeld of study. Given that developmental and clinical
opulations tend to move more than their common comparison
roups, there is a paramount need for improved strategies for col-
ecting high quality data.
. Conclusions
Neuroimaging studies of developmental and clinical popula-
ions present several challenges and issues for consideration at
he subject selection and data acquisition stage. Neuroimaging
s expensive, amplifying the importance of obtaining the high-
st quality data, losing as little data as possible, and generating
esults that have the highest potential for real-world application. Of
ourse, there are trade-offs that must be faced between the desire
o have a well-sampled, deeply characterized dataset and the cost
f acquiring such data in terms of both time and money. Funds and
esources are not always available to collect multiple T1-weighted
cans, 30 min  of resting state fMRI data, a full battery of clinical and
ehavioral measures with multiple informants, family studies or
horough family history, etc. Subject factors, such as comfort and
ime commitment, can limit the extent of the data collection as well.
hus, weighing the many trade-offs can lead to difﬁcult choices. Wee Neuroscience 18 (2016) 101–112
believe in two principled approaches to these decisions. (1) There
is no point in having useless MRI  data. Given the high cost involved
in neuroimaging and the susceptibility to movement artifact, every
attempt to collect useful (which sometimes translates to “enough”)
MRI  data should be employed. In our experiences with children
with TS, collecting two 5-min resting state fMRI scans resulted in
retaining only 50% of subjects due to movement, while collecting
three to four 7-min scans resulted in retaining 75% of subjects. Col-
lecting more data from each individual yielded signiﬁcantly less
wasted data, which we  consider well worth the up-front invest-
ment. (2) Omitting phenotyping altogether is, as the saying goes,
“penny-wise and pound-foolish.” Tough choices may  need to be
made with regard to the extent of phenotyping, but some level of
subject characterization is necessary in each of the most important
phenotypic domains for the population being studied. For instance,
several neuroimaging ﬁndings in studies of TS have proven to be
best interpreted only together with information on comorbid ADHD
(Castellanos et al., 1996; Gilbert et al., 2004). Depending on its
speciﬁc aims, a TS study may  require only a brief estimate of cur-
rent ADHD symptom severity or it may  require expert assessment
of lifetime ADHD diagnosis, but ignoring ADHD altogether would
be hard to justify. Again, it is well worth the up-front investment
to characterize the sample in order to obtain more interpretable
results.
Addressing the issues involved in subject selection and obtain-
ing adequate data is far from simple. As researchers, we must
carefully and thoughtfully justify our choices of methods and study
design. We should remain explicitly aware of our ultimate research
goals and become better equipped to justify our decisions in light of
those goals. As reviewers and critical readers of science, we  must
also have thoughtful rationale for our critiques of study designs
and results. Importantly, we  must be able to communicate this
reasoning clearly to peers and colleagues. Here, we  argue that
generalizability of results is a crucially important consideration,
as researchers should not strive for ﬁndings that hold true only
under particular circumstances, but rather for ﬁndings that emerge
regardless of methodological detail. Understanding the unintended
consequences of our methodological choices and clearly com-
municating the rationale for these choices will lead to better
science.
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